FCGR2A and breast carcinoma: Moreover, neutrophils activated via immunoglobulin receptor FcγR-antibody binding have also been established as necessary and sufficient for the monoclonal antibody induced immunotherapy of tumors in mouse models of melanoma and breast cancer [148].